A beta-adrenergic receptor kinase-like enzyme is involved in olfactory signal termination.
Abstract
We have previously shown that second-messenger-dependent kinases (cAMP-dependent kinase,
protein kinase C) in the olfactory system are essential in terminating second-messenger
signaling in response to odorants. We now document that subtype 2 of the beta-adrenergic
receptor kinase (beta ARK) is also involved in this process. By using subtype-specific
antibodies to beta ARK-1 and beta ARK-2, we show that beta ARK-2 is preferentially
expressed in the olfactory epithelium in contrast to findings in most other tissues.
Heparin, an inhibitor of beta ARK, as well as anti-beta ARK-2 antibodies, (i) completely
prevents the rapid decline of second-messenger signals (desensitization) that follows
odorant stimulation and (ii) strongly inhibits odorant-induced phosphorylation of
olfactory ciliary proteins. In contrast, beta ARK-1 antibodies are without effect.
Inhibitors of protein kinase A and protein kinase C also block odorant-induced desensitization
and phosphorylation. These data suggest that a sequential interplay of second-messenger-dependent
and receptor-specific kinases is functionally involved in olfactory desensitization.
Type
Journal articleSubject
AnimalsAntibodies
Cerebral Cortex
Chemoreceptor Cells
Cilia
Cyclic AMP-Dependent Protein Kinases
Epithelium
Heparin
Immune Sera
Kinetics
Odorants
Olfactory Pathways
Organ Specificity
Phosphorylation
Protein Kinase Inhibitors
Protein Kinases
Rats
Rats, Sprague-Dawley
Receptors, Adrenergic, beta
Signal Transduction
Smell
Time Factors
beta-Adrenergic Receptor Kinases
Permalink
https://hdl.handle.net/10161/7848Collections
More Info
Show full item recordScholars@Duke
Robert J. Lefkowitz
The Chancellor's Distinguished Professor of Medicine
Dr. Lefkowitz’s memoir, A Funny Thing Happened on the Way to Stockholm, recounts his
early career as a cardiologist and his transition to biochemistry, which led to his
Nobel Prize win.
Robert J. Lefkowitz, M.D. is James B. Duke Professor of Medicine and Professor of
Biochemistry and Chemistry at the Duke University Medical Center. He has been an Investigator
of the

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info
Related items
Showing items related by title, author, creator, and subject.
-
MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo.
Zennadi, Rahima (PLoS One, 2014)In sickle cell disease, sickle erythrocyte (SSRBC) interacts with endothelial cells, leukocytes, and platelets, and activates coagulation and inflammation, promoting vessel obstruction, which leads to serious life-threatening ... -
Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart.
Eckhart, AD; Duncan, SJ; Penn, RB; Benovic, JL; Lefkowitz, RJ; Koch, WJ (Circ Res, 2000-01-07)G protein-coupled receptor kinases (GRKs) phosphorylate activated G protein-coupled receptors, including alpha(1B)-adrenergic receptors (ARs), resulting in desensitization. In vivo analysis of GRK substrate selectivity has ... -
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
Kaufman, Jacob M; Yamada, Tadaaki; Park, Kyungho; Timmers, Cynthia D; Amann, Joseph M; Carbone, David P (Cancer research, 2017-01)LKB1 is a commonly mutated tumor suppressor in non-small cell lung cancer that exerts complex effects on signal transduction and transcriptional regulation. To better understand the downstream impact of loss of functional ...